Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Don Haut

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon Jan 08, 2021 6:37am

244 Views

Post# 32251916

RE:RE:RE:Don Haut

I believe it was highly important to get the news out before JP Morgan. I also think it's interesting to see that AskBio IPO was scrapped because BigPharma jumped in. BigPharma really waits to the last moment.

the hydrogen sulfide platform offers so many opportunities for future drugs targeting inflammation. How much will OTENA fetch? Exciting times!

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market